<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00950222</url>
  </required_header>
  <id_info>
    <org_study_id>P061014</org_study_id>
    <secondary_id>CRC06049</secondary_id>
    <nct_id>NCT00950222</nct_id>
  </id_info>
  <brief_title>Impact of Imipenem With Amikacin Pharmacokinetic and Pharmacodynamic</brief_title>
  <acronym>IMPACT</acronym>
  <official_title>Impact of Imipenem With Amikacin Pharmacokinetic and Pharmacodynamic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective open trial conducted in 4 centers, and designed to determine if&#xD;
      pharmacokinetic (PK) and pharmacodynamic (PD) parameters of imipenem, associated with&#xD;
      amikacin as empirical therapy, impact microbiological and clinical outcome of patients with&#xD;
      Gram negative bacilli (GNB) ventilator-associated pneumonia (VAP).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inappropriate initial antibiotherapy increases mortality of many serious infections. This is&#xD;
      the case for ventilator-associated pneumonia, frequently occurring during intensive care unit&#xD;
      (ICU) hospitalization, and whose 48 first hours of treatment are decisive.&#xD;
&#xD;
      It is well established that pharmacokinetic and pharmacodynamic parameters of antibiotics are&#xD;
      correlated with their clinical and microbiological effectiveness. However in ICU patients,&#xD;
      pharmacokinetic parameters of antibiotics suffer great variations, and bacteria responsible&#xD;
      for these infections are usually less sensitive to antibiotics, especially Gram negative&#xD;
      bacilli (GNB). An important pharmacodynamic variability may occur at the initial phase of the&#xD;
      antibiotic treatment, decisive for the infection's outcome.&#xD;
&#xD;
      We propose to evaluate the correlation between pharmacokinetic and pharmacodynamic profile of&#xD;
      the empirical antibiotic therapy and the microbiological and clinical outcome of VAP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variation of numeration (cfu per ml) of GNB, for whom culture of pulmonary samples are positive (higher than defined thresholds), between the quantitative endotracheal aspiration (QAE) obtained at H0 (initiation of treatment) and QAE obtained at H48</measure>
    <time_frame>Hour 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To describe imipenem and amikacin PK parameters as empirical therapy in ICU patients treated for VAP</measure>
    <time_frame>Hour 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe imipenem and amikacin PD parameters as empirical therapy in ICU patients treated for VAP</measure>
    <time_frame>Hour 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the proportion of patients for whom the pharmacodynamic targets suggested in the literature for aminoglycosides and beta lactams are achieved</measure>
    <time_frame>Hour 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To identify sources of variability of imipenem and amikacin PK/PD parameters in ICU patients with VAP</measure>
    <time_frame>Hour 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the impact of imipenem and amikacin PK/PD parameters on GNB eradication at day 3</measure>
    <time_frame>Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the impact of imipenem and amikacin PK/PD parameters variability on the CPIS, clinical score of VAP, measured 48 hours after initiation of the treatment</measure>
    <time_frame>Hour 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the impact of imipenem and amikacin PK/PD parameters on the time necessary to observe a CPIS lower or equal to 6</measure>
    <time_frame>Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the impact of imipenem and amikacin PK/PD parameters on clinical evolution of the VAP after 7 days of antibiotic treatment</measure>
    <time_frame>Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the impact of imipenem and amikacin PK/PD parameters on serum procalcitonin levels evolution between the initiation of the treatment and 48 hours after the initiation of the treatment of the VAP</measure>
    <time_frame>Hour 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the impact of imipenem and amikacin PK/PD parameters on mortality at day 28 (Day 28) 11- to assess the impact of imipenem and amikacin PK/PD parameters on VAP relapse</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To study emergence of less sensitive bacteria to imipenem and/or amikacin, 48 hours after the initiation of the antibiotic treatment, among GNB isolated in endotracheal aspiration before initiation of this treatment</measure>
    <time_frame>Hour 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To study emergence in the tracheal and digestive flora of micro-organisms resistant to imipenem after the first 48 hours of treatment by imipenem</measure>
    <time_frame>Hour 48</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Ventilator Associated Pneumonia</condition>
  <arm_group>
    <arm_group_label>1:Imipenem/Amikacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive as empirical therapy for VAP imipenem associated with amikacin.After primary outcome measure, antibiotic therapy will be left at the discretion of the physician in charge of the patient.&#xD;
Imipenem: recommended usual dosage for VAP treatment, IV (in the vein), every 8 hours&#xD;
Amikacin: recommended usual dosage for VAP treatment (20mg/kg), IV (in the vein), single dose (at H0) for the 48 first hours of treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipenem/Amikacin</intervention_name>
    <description>patients will received as empirical therapy for VAP imipenem associated with amikacin.</description>
    <arm_group_label>1:Imipenem/Amikacin</arm_group_label>
    <other_name>Therapy for VAP imipenem associated with amikacin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. Mechanical ventilation for more than 48 hours&#xD;
&#xD;
          3. Clinical suspicion of VAP defined by a new persistent radiological infiltrate and one&#xD;
             of the following signs: purulent tracheal aspirations, or temperature of 38°3 or&#xD;
             higher, or leucocyte count &gt; 10000/ml&#xD;
&#xD;
          4. Risk of multi resistant bacteria defined as follows: at least 6 days of mechanical&#xD;
             ventilation or antibiotic treatment in the 15 previous days&#xD;
&#xD;
          5. Distal pulmonary secretion sample obtained beforehand for microbiological diagnosis by&#xD;
             bronchoalveolar lavage via bronchoscopy or blinded protected telescoping catheter via&#xD;
             bronchoscopy or blindly&#xD;
&#xD;
          6. Presence of GNB on direct examination of the distal pulmonary secretion sample&#xD;
&#xD;
          7. Realization of a preliminary medical examination. 8- Written inform consent from the&#xD;
             patient or relatives. The consent may be obtained after the enrollment if the patient&#xD;
             is not able to give consent and if there is no relatives&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Time between distal pulmonary secretion sample taking and the 1st administration of&#xD;
             imipenem exceeding 24 hours&#xD;
&#xD;
          2. Pregnancy&#xD;
&#xD;
          3. Severely impaired renal function (creatinine clearance lower than 10 mL/mn or renal&#xD;
             replacement therapy)&#xD;
&#xD;
          4. Allergy to imipenem or amikacin&#xD;
&#xD;
          5. Treatment in progress with imipenem or amikacin&#xD;
&#xD;
          6. Death expected within 48 hours following diagnosis of VAP&#xD;
&#xD;
          7. Myasthenia&#xD;
&#xD;
          8. Simultaneous administration of others aminoglycosides&#xD;
&#xD;
          9. Association with intravenous polymyxin or botulinum toxin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier PAJOT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL ARGENTEUIL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Victor Dupouy Hospital</name>
      <address>
        <city>Argenteuil</city>
        <zip>95100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>July 28, 2009</study_first_submitted>
  <study_first_submitted_qc>July 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2009</study_first_posted>
  <last_update_submitted>July 25, 2012</last_update_submitted>
  <last_update_submitted_qc>July 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intensive care unit</keyword>
  <keyword>Ventilator associated pneumonia</keyword>
  <keyword>Gram negative bacilli infection</keyword>
  <keyword>Empirical antibiotic therapy</keyword>
  <keyword>Pharmacokinetic / pharmacodynamic</keyword>
  <keyword>Imipenem</keyword>
  <keyword>Amikacin</keyword>
  <keyword>Gram negative bacilli</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imipenem</mesh_term>
    <mesh_term>Amikacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

